Regulatory agencies and longevity developers are converging on pragmatic pathways that sidestep philosophical debates about aging's classification. The shift toward validated clinical outcome assessments and intrinsic capacity frameworks signals the field's transition from biomarker entertainment to demonstrable human benefit—the actual barrier to therapeutic approval.
Key Points
- Intrinsic Capacity framework scores locomotion, cognition, and vitality as separate domains, not com
- 87% of investigators identify validated surrogate endpoints as the primary barrier to longevity ther
- Existing drugs (SGLT2 inhibitors, metformin) show mortality reduction across aging-related outcomes
Longevity Analysis
The regulatory consensus abandons categorical arguments about whether aging constitutes disease in favor of measurable functional decline. This pragmatism removes a structural obstacle: developers can now demonstrate that slowing muscle loss, preserving gait speed, or maintaining cognitive processing delivers clinical value regulators can assess and approve. The focus shifts from theoretical frameworks to observable functional trajectories—whether someone maintains the physical and cognitive capacities required for independent living. This reorientation accelerates the translation of geroscience discoveries into approved therapeutics by working within existing regulatory infrastructure rather than demanding entirely new pathways. The convergence around intrinsic capacity metrics also standardizes how different interventions will be measured, reducing trial design uncertainty and lowering development costs.
Original published by Longevity.Technology, by Eleanor Garth.